Kodiak Sciences Inc. (KOD) Reports Complete Enrollment of DAZZLE Phase 2b/3 Pivotal Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Kodiak Sciences Inc. (KOD) Reports Complete Enrollment of DAZZLE Phase 2b/3 Pivotal Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration
November 18, 2020 5:49 AM EST
Kodiak Sciences Inc. (NASDAQ: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced the pricing of an underwritten public offering of 5,193,237 shares of its common stock at a price to the public of $108.00... More
November 16, 2020 3:21 AM EST
(Updated - November 16, 2020 5:47 AM EST)
(updating comment)
Morgan Stanley analyst Matthew Harrison downgraded Kodiak Sciences Inc. (NASDAQ: KOD) from Overweight to Equalweight with a price target of $125.00.
The analyst comments "We remain bullish on KSI-301's durability profile,... More
November 13, 2020 4:41 AM EST
(Updated - November 13, 2020 6:01 AM EST)
(updating comment)
Goldman Sachs analyst Graig Suvannavejh downgraded Kodiak Sciences Inc. (NASDAQ: KOD) from Buy to Neutral with a price target of $105.00.
The analyst comments "We raise our 12 month price target on Kodiak Sciences (KOD) to... More
November 12, 2020 10:45 AM EST
BMO Capital analyst Matthew Luchini raised the price target on Kodiak Sciences Inc. (NASDAQ: KOD) to $145.00 while maintaining an Outperform rating.
The analyst commented, "We are raising our target price to $145 on higher probability of success (67% vs. 45%) and peak US wAMD share (20% vs. 17%). Our... More
